Early onset sepsis in the newborn infant continues to be an important clinical problem for neonatologists everywhere in the world. Different routes of transmission, changes in causative agents, and potential antibiotic resistance all influence the choice of antibiotic therapy. Group B Streptococcus and Escherichia coli continue to be the major pathogens dictating antibiotic therapy in the United States. Ampicillin and gentamicin are the antibiotics used by most for empirical therapy; cephalosporins are used in certain clinical situations. In this review, we address the reasons for these choices while highlighting clinically relevant aspects of the antibiotics commonly used in the treatment of early onset sepsis in the newborn.

You do not currently have access to this content.